March 13th 2023
Shilpa Gupta, MD, discusses bladder preserving strategies for unfit or young patients, trials assessing immunotherapy combinations, and results from the BLASST-1 trial presented at ASCO GU.
February 20th 2023
February 18th 2023
Outcomes of the SARS-CoV-2 Infection in Patients with Cancer Treated in ChinaMarch 27th 2020
Researchers reported on the incidence and outcomes of the SARS-CoV-2 infection, which has been linked to COVID-19, in patients with cancer who were treated at a tertiary cancer institution in Wuhan, China.
FDA Approves First Agent to Treat Locally Advanced, Metastatic Urothelial CancerJanuary 15th 2020
The FDA approved enfortumab vedotin-ejfv (Padcev)-the first drug to treat adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy.
FDA Approves Pembrolizumab for Treatment of Certain Patients with NMIBCJanuary 8th 2020
The FDA approved pembrolizumab for the treatment of patients with BCG–unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in-situ with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.
FDA Grants Priority Review to Pembrolizumab for Non-Muscle Invasive Bladder CancerDecember 2nd 2019
The FDA has granted priority review to a supplemental biologics license application for pembrolizumab for the treatment of patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer.
Patients with Endometrial Cancer Pose High Risk of Dying from Cardiovascular DiseaseDecember 2nd 2019
Patients with endometrial cancer pose a very high risk of dying from cardiovascular diseases in the year after diagnosis, suggesting the necessity of early involvement of cardiologists for these patients.
Does Erdafitinib Show Clinical Benefit in Locally Advanced or Metastatic Urothelial Carcinoma?August 27th 2019
Erdafitinib is a tyrosine kinase inhibitor of fibroblast growth factor receptor 1 through 4 and was approved by the US Food and Drug Administration earlier this year as a second-line treatment for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations.
Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial CancerJanuary 17th 2019
In this review, we discuss known data and the differences between the different immune checkpoint inhibitors, as well as future avenues to explore with immuno-oncologic agents in urothelial cancer.
What Immunotherapy Combination Is Best in Metastatic Bladder Cancer?November 15th 2018
Extended follow-up from the CheckMate 032 trial showed strong results with three different immunotherapy regimens involving nivolumab and ipilimumab in patients with previously treated metastatic urothelial carcinoma.